The JI PBL Intereron Source
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Collins, E.
Right arrow Articles by Benjamin, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Collins, E.
Right arrow Articles by Benjamin, D.

The Journal of Immunology, Vol 135, Issue 2 886-891, Copyright © 1985 by American Association of Immunologists


ARTICLES

Tolerance to azobenzenearsonate: idiotype-specific suppression, B cell dominance, and clonal elimination

ET Collins, ED Hershey and DC Benjamin

Twenty to 70% of the antibody molecules produced by individual A/J mice in response to azobenzenearsonate (ABA) bear a particular idiotype termed the major cross-reactive idiotype (CRI). Mice that were made tolerant to ABA by injection of ABA coupled to human gamma-globulin show a decrease in production of ABA-specific antibody and a preferential loss of the major CRI. In the experiments reported here, we have used adoptive cell transfers and splenic fragment culture assays to study the mechanism(s) involved in the tolerance to ABA, with emphasis on the preferential loss of the CRI. These studies show that the decrease in total anti-ABA after the induction of tolerance is the result of a decrease in the number of ABA-responsive B cells independent of CRI expression. The preferential loss of the CRI is due to idiotype-specific T cell suppression and/or B cell dominance. In addition, it is demonstrated that immunization in the presence of idiotype-specific suppression converts a normally immunogenic stimulus into a tolerogenic signal, resulting in a decrease in the absolute number of CRI+ B cell precursors.





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 1985 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 1985 by The American Association of Immunologists, Inc. All rights reserved.